Full Archive
Patient characteristics, treatment patterns, and survival outcomes for patients with malignant pleural mesothelioma in Denmark between 2011 and 2018: a nationwide population-based cohort study
Acta Oncologica 2024 August 8 [Link] Jens Benn Sørensen, Paul Baas, Szimonetta Komjáthiné Szépligeti, Alma B Pedersen, Søren P Johnsen, Robert Carroll, Minouk J Schoemaker, Caroline Rault, Melinda J Daumont, Vera Ehrenstein Abstract Background: Malignant pleural mesothelioma (MPM) is a rare thoracic malignancy with poor prognosis and limited treatment options. Immunotherapy shows potential for improved…
Read MoreEnhancing the immunogenicity of Wilms tumor 1 epitope in mesothelioma cells with immunoproteasome inhibitors
PLoS One 2024 August 8 [Link] Masaki Ito, Shigeo Koido, Takeo Iwamoto, Soyoko Morimoto, Fumihiro Fujiki, Haruo Sugiyama, Saki Matsumoto, Clara Effenberger, Kazuma Kiyotani, Kiyotaka Shiba Abstract The immunogenicity of cancer cells is influenced by several factors, including the expression of the major histocompatibility complex class I (MHC-I), antigen expression, and the repertoire of proteasome-produced…
Read MoreChemotherapy increases CDA expression and sensitizes malignant pleural mesothelioma cells to capecitabine treatment
Scientific Reports 2024 August 6 [Link] Darya Karatkevich, Tereza Losmanova, Philipp Zens, Haibin Deng, Christelle Dubey, Tuo Zhang, Corsin Casty, Yanyun Gao, Christina Neppl, Sabina Berezowska, Wenxiang Wang, Ren-Wang Peng, Ralph Alexander Schmid, Patrick Dorn, Thomas Michael Marti Abstract The combination of cisplatin and pemetrexed remains the gold standard chemotherapy for malignant pleural mesothelioma (MPM),…
Read MoreApplication of the international system for reporting serous fluid cytopathology on pleural effusion cytology with paired pleural biopsy: A new insight and novel approach on risk of malignancy
Cytopathology 2024 August 1 [Link] Zahra Maleki, Ashleigh J Graham, Robert Jones, Ricardo Pastorello, Paul Morris, Alessandra C Schmitt, Erika F Rodriguez Abstract Introduction: The risk of malignancy (ROM) remains an area of interest for further evaluation in reporting systems including in International System for reporting serous fluid cytopathology (TIS), which is a standardized system…
Read MoreDevelopment in the Study of Natural Killer Cells for Malignant Peritoneal Mesothelioma Treatment
Cancer Biotherapy & Radiopharmaceuticals 2024 August 2 [Link] Yi-Tong Liu, He-Liang Wu, Yan-Dong Su, Yi Wang, Yan Li Abstract Malignant peritoneal mesothelioma (MPeM) is a rare primary malignant tumor originating from peritoneal mesothelial cells. Insufficient specificity of the symptoms and their frequent reappearance following surgery make it challenging to diagnose, creating a need for more…
Read MoreMajor response of a peritoneal mesothelioma to nivolumab and ipilimumab: a case report, molecular analysis and review of literature
Frontiers in Oncology 2024 July 18 [Link] Marie-Florence Reveneau, Julien Masliah-Planchon, Manuel Fernandez, Abdenour Ouikene, Bernard Dron, Innocenti Dadamessi, Charles Dayen, Lisa Golmard, Bruno Chauffert Abstract Malignant peritoneal mesothelioma (MPM) is a rare tumor associated with a poor prognosis and a lack of consensus regarding treatment strategies. While the Checkmate 743 trial demonstrated the superiority…
Read MoreResearch progress of malignant peritoneal mesothelioma with paraneoplastic syndrome: A review
Journal of Surgical Oncology 2024 July 31 [Link] Xin-Li Liang, Xin-Bao Li, Yu-Bin Fu, Yan-Dong Su, Ru Ma, Rui Yang, He-Liang Wu, Yan Li Abstract Malignant peritoneal mesothelioma (MPM) is a rare and invasive tumor, and some patients will develop paraneoplastic syndrome (PS) during the course of the disease. This review summarizes PS associated with…
Read MoreUpdate on gene fusions and the emerging clinicopathological landscape of peritoneal and pleural mesotheliomas and other neoplasms
ESMO Open 2024 July 25 [Link] N Benzerdjeb, P Dartigues, V Kepenekian, F Damiola, R Sequeiros, F Galateau-Salle, H Begueret, E Mery, D Damotte, V Verriele, J Fontaine, S Isaac, S Valmary-Degano, L Villeneuve, O Glehen, A Scherpereel, F Forest, A De la Fourchardiere, S Paindavoine, A Hourlier, D Pissaloux, F Tirode, S Lantuejoul Abstract…
Read MoreCombined detection of SHOX2 and PTGER4 methylation with serum marker CYFRA21-1 for improved diagnosis of malignant pleural mesothelioma
Journal of Clinical Pathology 2024 July 26 [Link] Nana Zhang, Yongmeng Li, Zuyu Sun, Yujie Dong, Lijuan Zhou, Chen Zhang, Zichen Liu, Qiuyi Zhang, Kun Li, Fudong Xu, Li Zhang, Bin She, Xiaosha Ren, Nanying Che Abstract Aims: To investigate the performance of a combined biomarker approach using the methylation status of the short stature…
Read MoreQuality of Life After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC): Cancer Survivors’ Perspective Through In-Depth Interviews
Annals of Surgical Oncology 2024 July 26 [Link] Luis Felipe Falla-Zuniga, Mary Caitlin King, Kathleen Pawlikowski, Andrei Nikiforchin, Felipe Lopez-Ramirez, Philipp Barakat, Sergei Iugai, Carol Nieroda, Vadim Gushchin, Armando Sardi Abstract Background: CRS/HIPEC patients face unique quality of life (QoL) challenges due to advanced disease (peritoneal carcinomatosis), the extent of procedure, and risk for long-term…
Read More